Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents

Neuropharmacology

Volumn 54, Issue 8, 2008, Pages 1254-1263

  Chipana, C ^a   Torres, I ^a   Camarasa, J ^a   Pubill, D ^a   Escubedo, E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alpha 7 nicotinic receptor; MDMA; Memantine; Methamphetamine; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; MEMANTINE; NICOTINIC RECEPTOR BLOCKING AGENT; PNU 282987; REACTIVE OXYGEN METABOLITE;

ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG DEPENDENCE; DRUG EFFECT; DRUG INHIBITION; HYPERTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMORY DISORDER; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE;

ANIMALS; BENZAMIDES; BICYCLO COMPOUNDS; BODY TEMPERATURE; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXCITATORY AMINO ACID ANTAGONISTS; HALLUCINOGENS; HIPPOCAMPUS; MALE; MEMANTINE; METHAMPHETAMINE; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROGLIA; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, NICOTINIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 44149107922     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.04.003     Document Type: Article

References (46)

1. Albers D.S., and Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and non protective agents. Journal of Pharmacology and Experimental Therapeutics 275 (1995) 1104-1114
2. Ali S.F., Newport G.D., Holson R.R., Slikker W., and Bowyer J.F. Low environmental temperatures or pharmacological agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Research 658 (1994) 33-38
3. Aracava Y., Pereira E.F.R., Maelicke A., and Albuquerque E.X. Memantine blocks alpha 7 nicotinic acetylcholine receptors more potently than N-methyl-d-aspartate receptors in rat hippocampal neurons. Journal of Pharmacology and Experimental Therapeutics 312 (2005) 1195-1205
4. Aznar S., Kostova V., Christiansen S.H., and Knudsen G.M. Alpha-7 nicotinic receptor subunit is present on serotonin neurons projecting to hippocampus and septum. Synapse 55 (2005) 196-200
5. 3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics 242 (1987) 911-916
6. Baumann M.H., Wang X.Y., and Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology 189 (2007) 407-424
7. Benavides J., Fage D., Carter C., and Scatton B. Peripheral type benzodiazepine binding-sites are a sensitive indirect index of neuronal damage. Brain Research 421 (1987) 167-172
8. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., and Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. Journal of Pharmacology and Experimental Therapeutics 268 (1994) 1571-1580
9. Chipana C., Camarasa J., Pubill D., and Escubedo E. Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors. Neuropharmacology 51 (2006) 885-895
10. Chipana C., García-Ratés S., Camarasa J., Pubill D., and Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxymethamphetamine. Neurochemistry International 52 (2008) 401-410
11. Chipana C., Camarasa J., Pubill D., and Escubedo E. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 29 (2008) 179-183
12. 3H] Win 35,428 Binding to the dopamine uptake carrier. 1. Effect of tonicity and buffer composition. Journal of Neuroscience Methods 51 (1994) 23-30
13. David H.N., Ansseau M., Lemaire M., and Abraini J.H. Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization. Biological Psychiatry 60 (2006) 49-57
14. 3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38 (1999) 679-690
15. Escubedo E., Guitart L., Sureda F.X., Jiménez A., Pubill D., Pallas M., Camins A., and Camarasa J. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Research 814 (1998) 120-126
16. Escubedo E., Chipana C., Pérez-Sánchez M., Camarasa J., and Pubill D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha 7 nicotinic receptors. Journal of Pharmacology and Experimental Therapeutics 315 (2005) 658-667
17. García-Ratés S., Camarasa J., Escubedo E., and Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation. Toxicology and Applied Pharmacology 223 (2007) 195-205
18. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological Reviews 55 (2003) 463-508
19. Jayanthi S., Ladenheim B., Andrews A.M., and Cadet J.L. Overexpression of human copper zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (ecstasy). Neuroscience 91 (1999) 1379-1387
20. Jiménez A., Jorda E.G., Verdaguer E., Pubill D., Sureda F.X., Canudas A.M., Escubedo E., Camarasa J., Camins A., and Pallas M. Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. Toxicology and Applied Pharmacology 196 (2004) 223-234
21. 3H]dopamine release in rat striatal slices via glutamate release. Molecular Pharmacology 58 (2000) 312-318
22. Kim S., Westphalen R., Callahan B., Hatzidimitriou G., Yuan J., and Ricaurte G.A. Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. Journal of Pharmacology and Experimental Therapeutics 293 (2000) 625-633
23. Klingler W., Heffron J.J.A., Jurkat-Rott K., O'Sullivan G., Alt A., Schlesinger F., Bufler J., and Lehmann-Horn F. 3,4-Methylenedioxymethamphetamine (ecstasy) activates skeletal muscle nicotinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics 314 (2005) 1267-1273
24. Kovacs G.G., Ando R.D., Adori C., Kirilly E., Benedek A., Palkovits M., and Bagdy G. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathology and Applied Neurobiology 33 (2007) 193-203
25. Levi M.S., and Borne R.F. A review of chemical agents in the pharmacotherapy of addiction. Current Medicinal Chemistry 9 (2002) 1807-1818
26. Leviel V. The reverse transport of DA, what physiological significance?. Neurochemistry International 38 (2001) 83-106
27. Maskell P.D., Speder P., Newberry N.R., and Bermudez I. The effects of the NMDA receptor antagonists cerestat and memantine on the human nicotinic alpha 7 receptor expressed in Xenopus oocytes. British Journal of Pharmacology 138 (2003) U105
28. Nair S.G., and Gudelsky G.A. Effect of a serotonin depleting regimen of 3,4-methylenedioxymethamphetamine (MDMA) on the subsequent stimulation of acetylcholine release in the rat prefrontal cortex. Brain Research Bulletin 69 (2006) 382-387
29. Orio L., O'Shea E., Sánchez V., Pradillo J.M., Escobedo I., Camarero J., Moro M.A., Green A.R., and Colado M.I. 3,4-Methylenedioxymethamphetamine increases interleukin-1 beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. Journal of Neurochemistry 89 (2004) 1445-1453
30. Panagis G., Kastellakis A., Spyraki C., and Nomikos G. Effects of methyllycaconitine (MLA), an alpha(7) nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward. Psychopharmacology 149 (2000) 388-396
31. Park C.H., Carboni E., Wood P.L., and Gee K.W. Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia 16 (1996) 65-70
32. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38 (1999) 735-767
33. Pubill D., Canudas A.M., Pallas M., Camins A., Camarasa J., and Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn-Schmiedeberg's Archives of Pharmacology 367 (2003) 490-499
34. Pubill D., Chipana C., Camins A., Pallas M., Camarasa J., and Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicology and Applied Pharmacology 204 (2005) 57-68
35. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 348 (2003) 1333-1341
36. Simon S.L., Domier C.P., Sim T., Richardson K., Rawson R.A., and Ling W. Cognitive performance of current methamphetamine and cocaine abusers. Journal of Addictive Diseases 21 (2002) 61-74
37. Solinas M., Scherma M., Fattore L., Stroik J., Wertheim C., Tanda G., Fratta W., and Goldberg S.R. Nicotinic alpha(7) receptors as a new target for treatment of cannabis abuse. Journal of Neuroscience 27 (2007) 5615-5620
38. Sprague J.E., Everman S.L., and Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19 (1998) 427-441
39. Straiko M.M.W., Coolen L.M., Zemlan F.P., and Gudelsky G.A. The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain. Neuroscience 144 (2007) 223-231
40. Thomasius R., Zapletalova P., Petersen K., Buchert R., Andresen B., Wartberg L., Nebeling B., and Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Journal of Psychopharmacology 20 (2006) 211-225
41. Turner T.J. Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. Journal of Neuroscience 24 (2004) 11328-11336
42. Unger C., Svedberg M.M., Schutte M., Bednar I., and Nordberg A. Effect of memantine on the alpha 7 neuronal nicotinic receptors, synaptophysin- and low molecular weight MAP-2 levels in the brain of transgenic mice over-expressing human acetylcholinesterase. Journal of Neural Transmission 112 (2005) 255-268
43. Upreti V.V., and Eddington N.D. Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. Journal of Pharmaceutical Sciences 97 (2008) 1593-1605
44. White S.R., Duffy P., and Kalivas P.W. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 62 (1994) 41-50
45. Yamamoto B.K., Nash J.F., and Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. Journal of Pharmacology and Experimental Therapeutics 273 (1995) 1063-1070
46. Yamamoto B.K., and Zhu W.J. The effects of methamphetamine on the production of free radicals and oxidative stress. Journal of Pharmacology and Experimental Therapeutics 287 (1998) 107-114